USA flag logo/image

An Official Website of the United States Government

Point of Injury Sampling Technology for Battlefield Molecular Diagnostics

Award Information

Agency:
Department of Defense
Branch:
Defense Advanced Research Projects Agency
Award ID:
Program Year/Program:
2012 / SBIR
Agency Tracking Number:
D2-1135
Solicitation Year:
2011
Solicitation Topic Code:
SB111-001
Solicitation Number:
2011.1
Small Business Information
OPTOFLUIDICS, INC.
3711 Market Street Philadelphia, PA 19104-5533
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2012
Title: Point of Injury Sampling Technology for Battlefield Molecular Diagnostics
Agency / Branch: DOD / DARPA
Contract: W31P4Q-12-C-0095
Award Amount: $1,375,238.00
 

Abstract:

In this project Optofluidics, Inc. proposes to develop the Molecular Medic a point-of-care device for sample collection, processing, and quantification of blood-borne biomarkers. The technology is based on (1) a finger prick assay, (2) a capillary-driven blood filtration system, (3) a novel"nanofluidic collapse"protein concentration technique and (4) a mutliplexable, reconfigurable, ultrasensitive Nanoscale Optofluidic Sensor Array. Key to the envisioned success of the Molecular Medic, is the combination of the most sensitive mass sensor (to our knowledge) with a novel concentration technique that, together will allow a point-of-care device to have comparable performance to a benchtop clinical test. The Molecular Medic builds on the success of the sample processing system that is currently nearing development completion in Phase I. Our initial focus is on diagnosing traumatic brain injury using a marker panel developed by our collaborators at Banyan Biomarkers. With nearly 2 million cases of TBI per year (globally) we expect to have a major impact beyond the military"s interest. With our devices untrained personnel, first responders or clinicians without convenient access to a clinical lab could diagnose with great certainty the presence of injuries and diseases and make more streamlined and informed decisions regarding treatment.

Principal Investigator:

Robert Hart
Principal Scientist
(215) 966-6251
hart@optofluidicscorp.com

Business Contact:

David Erickson
President and CEO
(215) 966-6251
erickson@optofluidicscorp.com
Small Business Information at Submission:

Optofluidics, Inc.
3711 Market Street, Suite 970 Philadelphia, PA -

EIN/Tax ID: 000000000
DUNS: N/A
Number of Employees:
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No